Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba1fa49d8a8ae93dcc76fe795abf43a46> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba1fa49d8a8ae93dcc76fe795abf43a46 NCIT_P378 "NCI" @default.
- Ba1fa49d8a8ae93dcc76fe795abf43a46 type Axiom @default.
- Ba1fa49d8a8ae93dcc76fe795abf43a46 annotatedProperty IAO_0000115 @default.
- Ba1fa49d8a8ae93dcc76fe795abf43a46 annotatedSource NCIT_C81569 @default.
- Ba1fa49d8a8ae93dcc76fe795abf43a46 annotatedTarget "The sodium salt form of ifetroban, an orally bioavailable thromboxane (TxA2) and prostaglandin H2 (PGH2) (TP) receptor antagonist, with anti-thrombotic, anti-hypertensive, anti-asthmatic and potential anti-metastatic activities. Upon administration, ifetroban targets and binds to TxA2 and PGH2 receptors, thereby preventing the activity of both TxA2 and PGH2 and disrupting their downstream signaling pathways. This prevents platelet activation, aggregation and thrombosis. It also prevents vascular constriction and causes vasodilation. In addition, as cancer cells use platelets to metastasize to different parts of the body, ifetroban can reduce the stickiness of the platelets and prevent metastasis. TxA2 causes vascular contraction and platelet activation." @default.